Posted by Michael Wonder on 21 Feb 2023
FDA accepts Orasis Pharmaceuticals' new drug application for CSF-1 for the treatment of presbyopia
21 February 2023 - Investigational, novel eye drop candidate was assigned PDUFA goal date of 22 October 2023.
Orasis Pharmaceuticals today announced that the US FDA has accepted for review its new drug application for investigational CSF-1 (0.4% pilocarpine hydrochloride).
